Torrent Pharmaceuticals has entered into a licensing agreement with Medicine Patent Pool (MPP) for manufacturing and commercializing the generic version of Pfizer’s oral Covid-19 treatment.

Pfizer’s oral Covid-19 treatment is made up of PAXLOVID (nirmatrelvir), which inhibits a SARS-CoV-2 protein to prevent the SARSCoV-2 virus from replicating and ritonavir, which slows down the breakdown of nirmatrelvir to help it stay in the body for a longer duration at higher concentrations.

The licensing agreement with Medicine Patent Pool is aimed at increasing wider access to Covid-19 treatment in 95 low‐ and middle-income countries, including India.

Previously, Medicine Patent Pool had signed a licensing deal with PF Prism Holdings, a subsidiary of Pfizer, to get the rights to sub-license manufacture and commercialization rights to sub-licensees.

Torrent Pharmaceuticals will launch the oral Covid-19 treatment after securing the required approval from regulatory agencies.

Aman Mehta — Executive Director of Torrent Pharmaceuticals said: “We are pleased to enter into this agreement with MPP and is part of our continued endeavor to make Covid treatments as accessible as possible to patients.”

  Aman Mehta, COVID-19, India, Medicine Patent Pool, nirmatrelvir, PAXLOVID, PF Prism Holdings, Pfizer, ritonavir, SARS-CoV-2, Torrent Pharmaceuticals